Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD

INTRODUCTION: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that has demonstrated safety and efficacy versus placebo in phase III trials in patients with anemia of chronic kidney disease (CKD) who were not on dialysis (NDD). METHODS: This was a phase III, active-control...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Kidney Int Rep
Main Authors: Akizawa, Tadao, Iwasaki, Manabu, Otsuka, Tetsuro, Yamaguchi, Yusuke, Reusch, Michael
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2021
Assuntos:
Clinical Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8258605/
https://ncbi.nlm.nih.gov/pubmed/34307976
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ekir.2021.04.003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados